Document is current
Any future updates will be listed below
-
Authors
Krause, Julia
Nickel, Alexander
Madsen, Alexandra
Aitken-Buck, Hamish M.
Stoter, A. M. Stella
Schrapers, Jessica
Ojeda, Francisco
Geiger, Kira
Kern, Melanie
Kohlhaas, Michael
Bertero, Edoardo
Hofmockel, Patrick
Hübner, Florian
Assum, Ines
Heinig, Matthias
Müller, Christian
Hansen, Arne
Krause, Tobias
Park, Deung-Dae
Just, Steffen
Aïssi, Dylan
Börnigen, Daniela
Lindner, Diana
Friedrich, Nele
Alhussini, Khaled
Bening, Constanze
Schnabel, Renate B.
Karakas, Mahir
Iacoviello, Licia
Salomaa, Veikko
Linneberg, Allan
Tunstall-Pedoe, Hugh
Kuulasmaa, Kari
Kirchhof, Paulus
Blankenberg, Stefan
Christ, Torsten
Eschenhagen, Thomas
Lamberts, Regis R.
Maack, Christoph
Stenzig, Justus
Zeller, Tanja https://orcid.org/0000-0003-3379-2641
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (STE 2596/4-1, ZE 1098/10-1)
Bundesministerium für Bildung und Forschung (01ZX1408A, 01ZX1408B, 01ZX1708)
Deutsches Zentrum für Herz-Kreislaufforschung (81Z0710102)
Seventh Framework Programme (HEALTH-F2-2011-278913)
European Research Area Network on Cardiovascular Diseases (01KL1807)
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 16 January 2023
Accepted: 7 August 2023
First Online: 24 August 2023
Declarations
:
: All participating cohort studies complied with the Declaration of Helsinki. Participants of all cohort studies gave written informed consent. The use of myocardial tissue for this study was approved by the local ethics board of the University Clinic Würzburg (ethics approval no. 143/17-sc). The use of serum samples for this study was approved by the local ethics board of the Dunedin Hospital, New Zealand (ethics approval no. #LRS12-01-001AM1-AM17). The BiomarCaRE studies were approved by the respective local ethics boards (FINRISK97: 82/2001, Moli-sani: Prot.pdc.P.99/A.931/03-128-04/C:E./2004, DanMONICA: 1980-272-2 1051NE/bt 2-16-2/43(85) KA 90238).
: All authors approved the current version of the manuscript and gave consent for submission and publication.
: The authors declare the following competing interests: TE and AH are co-founders of EHT Technologies GmbH, Hamburg. SB has received research funding from Abbott, Abbott Diagnostics, Bayer, Boehringer Ingelheim, Siemens, and ThermoFisher; honoraria for lectures from Abbott, Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Pfizer, Roche, Siemens Diagnostics, Siemens, and ThermoFisher; and honoraria for advisory board memberships and consulting for Boehringer Ingelheim, Bayer, Novartis, Roche, and ThermoFisher. CMa received honoraria for lectures from AstraZeneca, Berlin Chemie, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Novartis and Servier, and honoraria for advisory board memberships and consulting for Amgen, Boehringer Ingelheim, Novo Nordisk and Servier. RBS has received lecture fees and advisory board fees from BMS/Pfizer outside this work. AM is now an employee at AstraZeneca. JK is now an employee at Novo Nordisk since 2021. TZ and SB are listed as co-inventors of an international patent on the use of a computing device to estimate the probability of myocardial infarction (PCT/EP2021/073193, International Publication Number WO2022043229A1). TZ and SB are shareholders of the company ART-EMIS GmbH Hamburg.
